Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β-1b therapy

Annals of Neurology

Volumn 46, Issue 3, 1999, Pages 319-324

  Uhm, Joon H ^a,c   Dooley, Nora P ^a,c   Stuve, Olaf ^a,d   Francis, Gordon S ^a,e   Duquette, Pierre ^b   Antel, Jack P ^a   Yong, Voon Wee ^a,f  

^a MCGILL UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e EMD SERONO INC   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE MIGRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 0032880358     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199909)46:3<319::AID-ANA7>3.0.CO;2-N     Document Type: Article

References (32)

1. The IFNb Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
2. The IFNb Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon-β1α for disease progression in progression in relapsing multiple sclerosis. Ann Neural 1996;39:285-294
4. Fernández O, Antiquëdad A, Arbizu T, et al. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Multiple Sclerosis 1995;1:567-569
5. Paty DW, Li DKB, UBC/MS Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
6. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 1982;11:1-7
7. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996;64:91-100
8. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15
9. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-153
10. Noronha A, Toscas A, Jensen MA. Interferon-β augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27: 207-210
11. Stuve O, Dooley NP, Uhm JH, et al. Interferon-β1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863
12. Leppert D, Waubant E, Burk MR, et al. Interferon-β1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852
13. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-3245
14. Larocca AP, Leung SC, Marcus SG, et al. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res 1989;9(Suppl 1):S51-S60
15. DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994;30A: 2170-2180
16. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts: comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991;266: 14064-14071
17. Boone TC, Johnson MJ, DeClerck YA, Langley KE. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc Natl Acad Sci USA 1990;87:2800-2804
18. DeClerck YA, Yean TD, Ratzkin BJ, et al. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J Biol Chem 1989;264:17445-17453
19. Murphy G, Cawston T, Reynolds J. An inhibitor of collagenase from human amniotic fluid: purification, characterization and action on metalloproteinases. Biochem J 1981;195:167-170
20. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374-17378
21. Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas. Front Biosci 1999;4:188-199
22. Kent SJ, Karlik SJ, Cannon C, et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10
23. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-66
24. Calabresi PA, Pelfrey CM, Tranquill LR, et al. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997;49:1111-1116
25. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon beta-1b. J Clin Invest 1997;100:604-612
26. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-2334
27. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995;44:345-349
28. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182
29. Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 1998;44:35-46
30. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894
31. Calabresi PA, Frank JA, Maloni HW, et al. Association between neutralizing antibodies to interferon beta and contrast enhancing lesions in multiple sclerosis patients. Neurology 1997;48(Suppl 2):80 (Abstract)
32. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998;50:1266-1272